Treatment of cancers with A-8R peptide
AssigneeThe University of Toledo
InventorsLirim Shemshedini, Shao-Yong Chen, Changmeng Cai, Chen-Lin Hsieh
Life of this patent
Estimating the term…
Abstract
The present invention provides materials and methods useful to treat various sGCα1-expressing cancers. Materials include peptides which interfere with sGCα1's pro-survival functions, thereby resulting in apoptosis of sGCα1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits.
Claims6
A method to treat a patient with hormone-refractory prostate cancer in need of such treatment, comprising administering an effective amount of an isolated peptide consisting of the amino acid sequence of SEQ ID NO:5 to the patient.
A method to treat a patient with metastatic prostate cancer in need of such treatment, comprising administering an effective amount of an isolated peptide consisting of the amino acid sequence of SEQ ID NO:5 to the patient.
A method to treat a patient with late stage prostate cancer in need of such treatment, comprising administering an effective amount of an isolated peptide consisting of the amino acid sequence of SEQ ID NO:5 to the patient.
A method to treat a patient with an sCGα1-expressing pancreatic cancer in need of such treatment, comprising administering an effective amount of an isolated peptide consisting of the amino acid sequence of SEQ ID NO:5 to the patient.
A method to treat a patient with an sCGα1-expressing gastrointestinal cancer in need of such treatment, comprising administering an effective amount of an isolated peptide consisting of the amino acid sequence of SEQ ID NO:5 to the patient.
A method to treat a patient with a sCGα1-expressing cancer in need of such treatment, comprising administering an effective amount of an isolated peptide consisting of the amino acid sequence of SEQ ID NO:5 to the patient,
- wherein the cancer is selected from the group consisting of:
- neuroblastoma;
- lung cancer;
- bile duct cancer;
- non small cell lung carcinoma;
- hepatocellular carcinoma;
- nasopharyngeal carcinoma;
- gastric cancer;
- colon cancer;
- uterine cervical carcinoma;
- gall bladder cancer;
- prostate cancer;
- breast cancer;
- testicular germ cell tumors;
- colorectal cancer;
- glioma;
- thyroid cancer;
- basal cell carcinoma;
- gastrointestinal stromal cancer;
- hepatoblastoma;
- endometrial cancer;
- ovarian cancer;
- and urothelial cancer.
Dependencies are inferred from the claim text.